Abeona Therapeutics Inc (NASDAQ:ABEO) has earned an average recommendation of “Buy” from the eleven ratings firms that are currently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $30.14.

A number of research analysts have recently commented on ABEO shares. Royal Bank of Canada reiterated a “buy” rating and set a $26.00 target price on shares of Abeona Therapeutics in a research report on Wednesday, January 24th. SunTrust Banks started coverage on Abeona Therapeutics in a research report on Wednesday, November 8th. They issued a “buy” rating and a $26.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $30.00 price target (up from $20.00) on shares of Abeona Therapeutics in a research report on Monday, October 16th. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Wednesday, November 22nd. Finally, Maxim Group set a $35.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a research report on Monday, November 20th.

Abeona Therapeutics (NASDAQ:ABEO) traded down $1.48 during midday trading on Friday, hitting $14.08. The stock had a trading volume of 2,508,482 shares, compared to its average volume of 1,061,003. The company has a market cap of $727.35, a P/E ratio of -21.33 and a beta of 1.23. Abeona Therapeutics has a 52-week low of $4.55 and a 52-week high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. The firm had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.22 million. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. sell-side analysts predict that Abeona Therapeutics will post -0.6 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Virtus Fund Advisers LLC bought a new stake in Abeona Therapeutics in the fourth quarter worth $346,000. Virtu Financial LLC bought a new stake in Abeona Therapeutics in the fourth quarter worth $246,000. BlackRock Inc. lifted its position in Abeona Therapeutics by 15.1% in the fourth quarter. BlackRock Inc. now owns 1,868,378 shares of the biopharmaceutical company’s stock worth $29,614,000 after buying an additional 245,217 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Abeona Therapeutics by 89.8% in the fourth quarter. Bank of New York Mellon Corp now owns 195,474 shares of the biopharmaceutical company’s stock worth $3,097,000 after buying an additional 92,465 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its position in Abeona Therapeutics by 32.1% in the fourth quarter. Wells Fargo & Company MN now owns 46,529 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 11,311 shares during the last quarter. Institutional investors own 41.97% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Abeona Therapeutics Inc (ABEO) Receives Consensus Rating of “Buy” from Brokerages” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2018/02/10/abeona-therapeutics-inc-abeo-receives-consensus-rating-of-buy-from-brokerages.html.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.